ArticleClinicoEconomics and outcomes research : CEOR2026

Early Health Technology Assessment (HTA) of Olpasiran and Pelacarsen for Secondary Prevention of Coronary Heart Disease (CHD).

Elena Filipova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.